We will be at CIMT 2019

    

 

Else Marit Inderberg, Sebastien Wälchli, Nadia Mensali and Elizabeth Baken will attend CIMT 2019 meeting in Mainz (21 to 23 May).

Make sure to look at their abstracts.

CIMT website

CIMT program

First norwegian CAR publication!

We published pre-clinical results of the first 100% Norwegian CAR: CD37CAR, an alternative to CD19CAR.

Make sure to have a look here and here !

Hakan Köksal And Pierre Dillard are first authors of this publication.

 

We will be at AACR 2019

 

Gunnar Kvalheim, Hakan Köksal and Pierre Dillard will be at the next AACR meeting (29th of March to 3rd of April, Atalanta) to talk about new developments in CAR.

Hakan will present a novel combination method for IGKCAR that prevents B-cell aplasia.

Pierre will present the pre-clinical validation of CD37CAR, an alternative to CD19CAR.

Make sure to have a look!

A new Postdoc joined us !

Emmanuelle Benard who did her PhD in Biophysics and Immunology in Marseille, just joined us ! 

She will be in charge of the development of new CAR T-cells.

First JOVE shooting

We had our first JOVE shooting on a new metod to generate spheroid for CAR T-cells screening.

Make sure to give it a look (once it is out) !

 

PIVAC 2018 was held in Oslo

PIVAC 2018 was held in Oslo, co-organized by the department of Cell Therpay. The conference permitted to share new advance in the field of vaccination and future prospects for immunotherapy. 

We will be at CIMT 2018!

    

 

Gunnar Kvalheim, Else Marit Inderberg, Sebastien Wälchli and Nadia Mensali will attend CIMT 2018 meeting in Mainz (15 to 17 May).

Make sure to look at their abstracts.

CIMT website

CIMT program

We will be at AACR 2018

 

 

Pierre Dillard will attend the 2018 meeting of the American Association for Cncer Research (AACR). He will present our recent work on universal killer, make sure to have a look !

New publication from our group in Cancer Immunology

Human c-SRC kinase (CSK) overexpression makes T cells dummy

Patient safety upon immunotherapy treatment is a challenge that still need to be adressed.

In this publication we report how by affecting c-SRC kinase we can make T-cells "dummy": effector cells are still able to recognize and bind to the target but unable to carry on with their activation. This mechanism could potentially open the way for a safe-lock system permitting to reduce off-target toxicity.

Image from: Ellen Tenstad/Science Shaped

We will be at SITC 2017 !

 

Nadia Mensali and Pierre Dillard will attend the 2017 meeting of the Society for ImmunoTherapy of Cancer (SITC). They will present our recent work on universal killer and CD4 Adoptive cell therapy, make sure to have a look !

We will be at PIVAC 2017 at the end of September

 Marit Renee Myhre has been selected to give a talk at  the 17th International Conference on Progress in  Vaccination Against Cancer (PIVAC 2017) in Loutraki,  Corinth, Greece

 She will present our latest work on our new CD4-based therapy, make sure to have a look at the abstract if you want  to learn more !